Gail Wilensky - UnitedHealth Group Independent Director
| UNH Stock | USD 516.85 5.55 1.09% |
Director
Dr. Gail R. Wilensky, Ph.D. is Independent Director of the Company. Dr. Wilensky was a senior fellow at Project HOPE, an international health foundation, since 1993. From 2008 to 2009, Dr. Wilensky was President of the Department of Defense Health Board and chaired its subcommittee on health care delivery. From 2006 to 2008, Dr. Wilensky cochaired the Department of Defense Task Force on the Future of Military Health Care. During 2007 she also served as a commissioner on the President Commission on Care for America Returning Wounded Warriors. From 2001 to 2003, she was the CoChair of the President Task Force to Improve Health Care for our Nation Veterans. From 1997 to 2001, she was also Chair of the Medicare Payment Advisory Commission. From 1992 to 1993, Dr. Wilensky served as the Deputy Assistant to President George H. W. Bush for policy development, and from 1990 to 1992, she was the Administrator of the Health Care Financing Administration directing the Medicaid and Medicare programs for the United States. Dr. Wilensky is a nationally recognized health care economist. Dr. Wilensky currently serves as a director of Quest Diagnostics Incorporated. since 1993.
| Age | 76 |
| Tenure | 32 years |
| Address | 1 Health Drive, Eden Prairie, MN, United States, 55344 |
| Phone | (800)-328-5979 |
| Web | https://www.unitedhealthgroup.com |
UnitedHealth Group Management Efficiency
The company has Return on Asset of 0.0706 % which means that on every $100 spent on assets, it made $0.0706 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1513 %, implying that it generated $0.1513 on every 100 dollars invested. UnitedHealth Group's management efficiency ratios could be used to measure how well UnitedHealth Group manages its routine affairs as well as how well it operates its assets and liabilities. As of now, UnitedHealth Group's Return On Tangible Assets are increasing as compared to previous years. The UnitedHealth Group's current Return On Capital Employed is estimated to increase to 0.21, while Return On Equity is projected to decrease to 0.1. As of now, UnitedHealth Group's Intangible Assets are increasing as compared to previous years. The UnitedHealth Group's current Return On Tangible Assets is estimated to increase to 0.09, while Non Currrent Assets Other are projected to decrease to under 12.5 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| David Steward | Centene Corp | 68 | |
| Karen Katz | Humana Inc | 64 | |
| Daniel Cooperman | Molina Healthcare | 70 | |
| Garrey Carruthers | Molina Healthcare | 80 | |
| William McDonald | Humana Inc | 64 | |
| James OBrien | Humana Inc | 66 | |
| NancyAnn DeParle | CVS Health Corp | 64 | |
| Roman Martinez | Cigna Corp | 71 | |
| Alecia DeCoudreaux | CVS Health Corp | 66 | |
| Frank DAmelio | Humana Inc | 63 | |
| John Roberts | Centene Corp | 78 | |
| Dale Wolf | Molina Healthcare | 66 | |
| Roger Farah | CVS Health Corp | 72 | |
| William Weldon | CVS Health Corp | 72 | |
| David Jones | Humana Inc | 71 | |
| William Trubeck | Centene Corp | 74 | |
| JeanPierre Millon | CVS Health Corp | 70 | |
| Robert Ditmore | Centene Corp | 86 | |
| Frank Bisignano | Humana Inc | 62 | |
| John Partridge | Cigna Corp | 71 | |
| Anne Finucane | CVS Health Corp | 68 | |
Management Performance
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0706 |
UnitedHealth Group Leadership Team
Elected by the shareholders, the UnitedHealth Group's board of directors comprises two types of representatives: UnitedHealth Group inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UnitedHealth. The board's role is to monitor UnitedHealth Group's management team and ensure that shareholders' interests are well served. UnitedHealth Group's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UnitedHealth Group's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gail Wilensky, Independent Director | ||
| Richard Burke, Independent Chairman of the Board | ||
| Brian CPA, Chief UnitedHealthcare | ||
| Valerie Rice, Independent Director | ||
| Andrew Witty, Group President, Chief Executive Officer, Executive Vice President, Director | ||
| Terry Clark, Executive Officer | ||
| Sir Witty, CEO Director | ||
| Stephen Hemsley, Non-Executive Chairman of the Board | ||
| John Rex, Chief Financial Officer, Executive Vice President | ||
| Dirk McMahon, President and Chief Operating Officer; Chief Executive Officer of UnitedHealthcare | ||
| Zachary Sopcak, Senior Relations | ||
| Erin McSweeney, Executive Officer | ||
| Chris Zaetta, Chief VP | ||
| John Noseworthy, Independent Director | ||
| Jennifer Smoter, Senior Officer | ||
| William Ballard, Independent Director | ||
| Glenn Renwick, Independent Director | ||
| Rupert Bondy, Compliance Governance | ||
| Sandeep Dadlani, Executive Officer | ||
| Michele Hooper, Lead Independent Director | ||
| Timothy Flynn, Independent Director | ||
| Thomas Roos, Senior Vice President, Chief Accounting Officer | ||
| Matthew Friedrich, Executive Vice President Chief Legal Officer | ||
| D Wilson, Executive Vice President - Human Capital | ||
| F McNabb, Independent Director | ||
| Paul Garcia, Independent Director | ||
| Marianne Short, Executive Vice President, Chief Legal Officer | ||
| David Wichmann, Chief Executive Officer, Director | ||
| Patricia Lewis, Chief Human Resource Officer, Executive Vice President | ||
| Christopher Zaetta, Chief VP | ||
| Brian Thompson, Executive UnitedHealthcare | ||
| James Barry, Director Pennsylvania |
UnitedHealth Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is UnitedHealth Group a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0706 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 515.48 B | ||||
| Shares Outstanding | 914.71 M | ||||
| Shares Owned By Insiders | 0.24 % | ||||
| Shares Owned By Institutions | 90.30 % | ||||
| Number Of Shares Shorted | 8.69 M | ||||
| Price To Earning | 26.34 X |
Currently Active Assets on Macroaxis
When determining whether UnitedHealth Group offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of UnitedHealth Group's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Unitedhealth Group Incorporated Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Unitedhealth Group Incorporated Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UnitedHealth Group Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UnitedHealth Group. If investors know UnitedHealth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UnitedHealth Group listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.026 | Dividend Share 8.18 | Earnings Share 15.49 | Revenue Per Share | Quarterly Revenue Growth 0.068 |
The market value of UnitedHealth Group is measured differently than its book value, which is the value of UnitedHealth that is recorded on the company's balance sheet. Investors also form their own opinion of UnitedHealth Group's value that differs from its market value or its book value, called intrinsic value, which is UnitedHealth Group's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UnitedHealth Group's market value can be influenced by many factors that don't directly affect UnitedHealth Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UnitedHealth Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if UnitedHealth Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UnitedHealth Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.